Madrigal reports supportive MAESTRO-NASH consensus read; NASH resolution and fibrosis improvement remain significant

MADRIGAL PHARMACEUTICALS, INC.

Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).
Fibrosis improvement ≥1 stage: 24% (80mg) and 26% (100mg) vs 12% placebo (p<0.0001).
Analysis used digitized biopsies when two pathologists' scores disagreed on primary endpoints.
Results consistent with primary analysis announced Dec 19, 2022; trial continues for up to 54 months.
Data presented at NASH-TAG Conference on Jan 6, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.